Supplementary Tables: Supplementary Materials. The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark

Table S1: Baseline Characteristics.Table S2: Treatment Effects – First Line.Table S3: Adverse Events.Table S4: Treatment effects for second/third line treatments (treatment policy estimand).Table S5: Proportion of patients on preventive medication.Table S6: Screening and patient management proportions.Table S7: Sensitivity and specificity of tests.Table S8 Annual treatment costs applied (DKK, AIP 2020, [20]).Table S9 Cost Inputs for the CDM (Costs inflated to 2020 values, DKK).Table S10: Utilities used in CDM.Table S11: Scenario analysis results.Table S12: Breakdown of costs (DKK, per average patient).

表 S1：基线特征。表 S2：治疗方案效果——一线治疗。表 S3：不良事件。表 S4：二线/三线治疗方案的效果（治疗政策估计量）。表 S5：接受预防性药物患者的比例。表 S6：筛查和患者管理比例。表 S7：测试的灵敏度和特异性。表 S8：年度治疗成本（丹麦克朗，AIP 2020，[20]）。表 S9：CDM 成本输入（成本按 2020 年值通胀，丹麦克朗）。表 S10：CDM 中使用的效用。表 S11：情景分析结果。表 S12：成本分解（丹麦克朗，按平均患者计算）。